Managers / Q4 2019 · view latest →
Eversept Partners, LP
CIK 0001697013 · 444 MADISON AVENUE, 22ND FLOOR, NEW YORK, NY, 10022 · 212-271-4200
Reported Value
$516M
Q4 2019
Positions
75
Filings on Record
63
2019–present window
Filed
Feb 13, 2020
original filing
Summary
Eversept Partners, Lp reported $516M in U.S.-listed holdings across 75 positions for Q4 2019.
Its largest position, Glaxosmithkline, represents 9.4% of the portfolio.
Compared with Q3 2019, the fund opened 28 new positions and exited 12.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
Composition data arrives with ticker enrichment.
Quarter-over-Quarter Changes full breakdown →
Holdings — Q4 2019
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $1.9B | 120 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $2.0B | 107 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $1.5B | 86 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $1.1B | 68 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $985M | 57 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $1.1B | 65 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $1.5B | 67 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $1.5B | 74 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $1.5B | 70 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $1.1B | 57 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $1.2B | 69 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $966M | 71 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $1.1B | 62 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $1.08T | 64 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $978M | 69 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $1.2B | 76 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $1.2B | 86 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $1.4B | 105 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.3B | 102 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.3B | 87 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.3B | 83 | May 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $841M | 60 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $445M | 48 | Nov 13, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $619M | 71 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $395M | 65 | May 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $516M | 75 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $320M | 59 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $351M | 64 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $339M | 54 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $181M | 59 | Feb 13, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.